⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12825489 | 0.83 | — | — | |
| SCHEMBL874203 | 0.80 | — | — | |
| SCHEMBL6718290 | 0.76 | — | — | |
| SCHEMBL2493955 | 0.76 | — | — | |
| SCHEMBL30229716 | 0.76 | — | — | |
| SCHEMBL12506114 | 0.76 | — | — | |
| SCHEMBL8201056 | 0.74 | — | — | |
| SCHEMBL1628118 | 0.72 | — | — | |
| SCHEMBL25036986 | 0.72 | — | — | |
| SCHEMBL1368468 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4605394-A1 | PYRIMIDINE SGC STIMULATORS | Tisento Therapeutics Inc. (US) | 2025-08-27 | — | — | EP | disclosed |
| WO-2024086179-A1 | PYRIMIDINE SGC STIMULATORS | TISENTO THERAPEUTICS, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20230219940-A1 | PROCESS FOR THE PREPARATION OF FLUOXASTROBIN AND INTERMEDIATES THEREOF | UPL LTD (IN) | 2023-07-13 | — | — | US | disclosed |
| EP-2906555-B1 | PROCESS FOR THE PREPARATION OF VORICONAZOLE AND ANALOGUES THEREOF | PFIZER IRELAND PHARMACEUTICALS (IE) | 2016-12-14 | — | — | EP | disclosed |
| US-9499520-B2 | Process for the preparation of voriconazole and analogues thereof | PFIZER IRELAND PHARMACEUTICALS (IE) | 2016-11-22 | — | — | US | disclosed |
| US-9499520-B2 | Process for the preparation of voriconazole and analogues thereof | PFIZER IRELAND PHARMACEUTICALS (IE) | 2016-11-22 | — | — | US | disclosed |
| US-20160229842-A1 | Process for the Preparation of Voriconazole and Analogues Thereof | PFIZER IRELAND PHARMACEUTICALS (IE) | 2016-08-11 | — | — | US | disclosed |
| US-20160229842-A1 | Process for the Preparation of Voriconazole and Analogues Thereof | PFIZER IRELAND PHARMACEUTICALS (IE) | 2016-08-11 | — | — | US | disclosed |
| US-9388167-B2 | Process for the preparation of voriconazole and analogues thereof | PFIZER IRELAND PHARMACEUTICALS (IE) | 2016-07-12 | — | — | US | disclosed |
| US-9388167-B2 | Process for the preparation of voriconazole and analogues thereof | PFIZER IRELAND PHARMACEUTICALS (IE) | 2016-07-12 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090137547-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. | 2009-05-28 | — | — | US | disclosed |
| US-20090062310-A1 | DEUTERIUM-ENRICHED VORICONAZOLE | PROTIA, LLC (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090062310-A1 | DEUTERIUM-ENRICHED VORICONAZOLE | PROTIA, LLC (US) | 2009-03-05 | — | — | US | disclosed |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | BLUHM HARALD | 2008-09-11 | — | — | US | disclosed |
| US-20080221092-A1 | Heterobicyclic metalloprotease inhibitors | BLUHM HARALD | 2008-09-11 | — | — | US | disclosed |
| WO-2008063669-A1 | HETEROBICYCLIC MATRIX METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |